Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN01194 First-in-Human in Advanced Solid Tumors
2023-506228-10-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ipn01194 in melanoma, colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 2 more (2 arms), sponsored by Ipsen. Primary endpoints: Phase 1: Percentage of participants with dose limiting toxicity (DLT), Phase 1: Percentage of participants experiencing treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TE SAEs) and 2 more. Planned start Apr 2024; status: authorised.
02
Drugs
ipn01194
03
Conditions
melanomacolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-506228-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506228-10-00.